PHYX Physiometrix (MM)

Scimitar Equity Research Issues Review on Physiometrix, Inc. BOSTON, Nov. 8 /PRNewswire/ -- Scimitar Equity Research, Inc. (Scimitar) issued a review on Physiometrix, Inc. (NASDAQ:PHYX) entitled "Momentum and Sales Drive Positive Q3 Revenues...Increasing Market Penetration." The analyst research review is available on Scimitar's website; http://www.scimitarequity.com/. Scimitar Equity Research, Inc. provides unbiased research and insightful analysis of the health sciences industry for the institutional and investment communities. Scimitar does not own any securities related to the companies we provide analysis or develop research products. We will not have investment banking relationships with any company to maintain our independence and objectivity. Investors are advised that this analysis and review is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy. Scimitar was paid for preparing this review. This analysis and review does not have regard to the specific investment objectives, financial situation and the information contained herein is based on sources that we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. Any opinions expressed are statements of our own judgment as of the date of publication and are subject to change without notice. CONTACT: Scimitar Equity Research, Inc. Henry W. McCusker Director of Research phone: (617) 236-6396 fax: (617) 236-6397 e-mail: DATASOURCE: Scimitar Equity Research CONTACT: Henry W. McCusker, Director of Research of Scimitar Equity Research, Inc., +1-617-236-6396, Web site: http://www.scimitarequity.com/

Copyright